Terms: = Sarcomas AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Treatment
67 results:
1. Principles in the Management of Glioblastoma.
Roda D; Veiga P; Melo JB; Carreira IM; Ribeiro IP
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674436
[TBL] [Abstract] [Full Text] [Related]
2. A personalized medicine approach identifies enasidenib as an efficient treatment for idh2 mutant chondrosarcoma.
Rey V; Tornín J; Alba-Linares JJ; Robledo C; Murillo D; Rodríguez A; Gallego B; Huergo C; Viera C; Braña A; Astudillo A; Heymann D; Szuhai K; Bovée JVMG; Fernández AF; Fraga MF; Alonso J; Rodríguez R
EBioMedicine; 2024 Apr; 102():105090. PubMed ID: 38547578
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Profile of Intrahepatic Cholangiocarcinoma.
Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
[TBL] [Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. Epilepsy in gliomas: recent insights into risk factors and molecular pathways.
Rudà R; Bruno F; Pellerino A
Curr Opin Neurol; 2023 Dec; 36(6):557-563. PubMed ID: 37865836
[TBL] [Abstract] [Full Text] [Related]
6. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Subbiah V; Chawla SP; Conley AP; Wilky BA; Tolcher A; Lakhani NJ; Berz D; Andrianov V; Crago W; Holcomb M; Hussain A; Veldstra C; Kalabus J; O'Neill B; Senne L; Rowell E; Heidt AB; Willis KM; Eckelman BP
Clin Cancer Res; 2023 Aug; 29(16):2988-3003. PubMed ID: 37265425
[TBL] [Abstract] [Full Text] [Related]
7. Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution.
Abdulfatah E; Rottmann D; Morag Y; Pantanowitz L; Udager AM; Hao W; Lucas DR
Hum Pathol; 2023 Jun; 136():63-74. PubMed ID: 37019410
[TBL] [Abstract] [Full Text] [Related]
8. Gene Mutations and Targeted Therapies of Myeloid Sarcoma.
Fu L; Zhang Z; Chen Z; Fu J; Hong P; Feng W
Curr Treat Options Oncol; 2023 Apr; 24(4):338-352. PubMed ID: 36877373
[TBL] [Abstract] [Full Text] [Related]
9. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract] [Full Text] [Related]
10. Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.
Palubeckaitė I; Venneker S; van den Akker BEWM; Briaire-de Bruijn IH; Boveé JVMG
Clin Orthop Relat Res; 2023 Mar; 481(3):608-619. PubMed ID: 36729612
[TBL] [Abstract] [Full Text] [Related]
11. Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and treatment Options.
Tlemsani C; Larousserie F; De Percin S; Audard V; Hadjadj D; Chen J; Biau D; Anract P; Terris B; Goldwasser F; Pasmant E; Boudou-Rouquette P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674874
[TBL] [Abstract] [Full Text] [Related]
12. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
[TBL] [Abstract] [Full Text] [Related]
13. Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.
Lazaridis L; Schmidt T; Oster C; Blau T; Pierscianek D; Siveke JT; Bauer S; Schildhaus HU; Sure U; Keyvani K; Kleinschnitz C; Stuschke M; Herrmann K; Deuschl C; Scheffler B; Kebir S; Glas M
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3513-3526. PubMed ID: 35953681
[TBL] [Abstract] [Full Text] [Related]
14. Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an idh1 R132C mutation: a case report.
Lv H; Jiang H; Zhang M; Luo H; Hong Z; Yang H; Xu W; Shen B; Zhang W; Qiu H; Zhu R
World J Surg Oncol; 2022 Jun; 20(1):218. PubMed ID: 35765075
[TBL] [Abstract] [Full Text] [Related]
15. Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of midh1 Mutant Tumours.
Weber V; Arnaud L; Dukic-Stefanovic S; Wenzel B; Roux V; Chezal JM; Lai TH; Teodoro R; Kopka K; Miot-Noirault E; Deuther-Conrad W; Maisonial-Besset A
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744895
[TBL] [Abstract] [Full Text] [Related]
16. idh1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract] [Full Text] [Related]
17. Systemic Therapy for Chondrosarcoma.
Rock A; Ali S; Chow WA
Curr Treat Options Oncol; 2022 Feb; 23(2):199-209. PubMed ID: 35190971
[TBL] [Abstract] [Full Text] [Related]
18. Therapeutic Targets and Emerging treatments in Advanced Chondrosarcoma.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163019
[TBL] [Abstract] [Full Text] [Related]
19. Myeloid Sarcoma Involving the Testis in Adults: Clonal Evolution of Acute Myeloid Leukemia.
Nichols MM; Cook JR; Bosler DS; Rogers HJ; Philip JKSS; Jogenpally NR; Reynolds JP; Robertson S; Cotta CV
Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):e32-e39. PubMed ID: 35001036
[TBL] [Abstract] [Full Text] [Related]
20. Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors.
Sheikh TN; Chen X; Xu X; McGuire JT; Ingham M; Lu C; Schwartz GK
Mol Cancer Ther; 2021 Dec; 20(12):2362-2371. PubMed ID: 34552007
[TBL] [Abstract] [Full Text] [Related]
[Next]